Column Group IV GP, LP - 06 Feb 2026 SCHEDULE 13D Report for Eikon Therapeutics, Inc. Common Stock, $0.0001 par value per share (SRZN)

Filing Manager
Column Group IV GP, LP
Reporting Manager
Tim Kutzkey
Security
Eikon Therapeutics, Inc. Common Stock, $0.0001 par value per share
Symbol
SRZN
Shares outstanding
54,773,379 shares
Disclosed Ownership
6,353,712 shares
Ownership
12%
Form type
SCHEDULE 13D
Filing time
12 Feb 2026, 18:48:54 UTC
Date of event
06 Feb 2026
SEC
View on sec.gov

Reporting Managers (8)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
The Column Group IV GP, LP 8.3% 4,460,979 0 4,460,979 /s/ James Evangelista James Evangelista, Attorney-in-Fact 0001796356
The Column Group IV, LP 8% 4,312,139 0 4,312,139 /s/ James Evangelista James Evangelista, Attorney-in-Fact 0001796354
The Column Group IV-A, LP 0.3% 148,840 0 148,840 /s/ James Evangelista James Evangelista, Attorney-in-Fact 0001796353
The Column Group Opportunity III, LP 3.5% 1,892,733 0 1,892,733 /s/ James Evangelista James Evangelista, Attorney-in-Fact 0001931825
The Column Group Opportunity III GP, LP 3.5% 1,892,733 0 1,892,733 /s/ James Evangelista James Evangelista, Attorney-in-Fact 0001932874
TCG Opportunity III GP, LLC 3.5% 1,892,733 0 1,892,733 /s/ James Evangelista James Evangelista, Attorney-in-Fact 0001932445
Tim Kutzkey 12% 6,353,712 0 6,353,712 /s/ James Evangelista James Evangelista, as Attorney-in-Fact for Tim Kutzkey 0001614186
Peter Svennilson 12% 6,353,712 0 6,353,712 /s/ James Evangelista James Evangelista, as Attorney-in-Fact for Peter Svennilson 0001606074